BMS-986358 / BMS - LARVOL DELTA

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=9 | Terminated | Sponsor: Celgene | Completed ➔ Terminated; Business objectives have changed.

Trial termination • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: Celgene | Active, not recruiting ➔ Completed | N=100 ➔ 9 | Trial completion date: Aug 2025 ➔ Jul 2024 | Trial primary completion date: Aug 2025 ➔ Jul 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CC-96673 (BMS-986358), An Affinity Tuned Anti-CD47 and CD20 Bispecific Antibody with Fully Functional Fc, Selectively Targets and Depletes Non-Hodgkin’s Lymphoma (FOB-USA 2024) - "Furthermore, preclinical studies have demonstrated that CC-96673 exhibits acceptable pharmacokinetic (PK) properties with a favourable toxicity profile in non-human primate. Collectively, these findings define CC-96673 as a promising CD47xCD20 bispecific antibody that selectively destroys CD20+ cancer cells via enhanced phagocytosis and other effector functions."

IO biomarker • Anemia • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • SIRPA

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma. (PubMed, MAbs) - "Furthermore, preclinical studies have demonstrated that CC-96673 exhibits acceptable pharmacokinetic properties with a favorable toxicity profile in non-human primates. Collectively, these findings define CC-96673 as a promising CD47 × CD20 bispecific antibody that selectively destroys CD20+ cancer cells via enhanced phagocytosis and other effector functions."

IO biomarker • Journal • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • SIRPA

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=100 | Active, not recruiting | Sponsor: Celgene | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2029 ➔ Aug 2025

Enrollment closed • Trial completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology